Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Quick facts
Phase 3 pipeline
- IBI112 · Oncology
IBI112 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. portfolio CI brief
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. pipeline updates RSS
Frequently asked questions about Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
What is Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.'s pipeline?
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include IBI112.
Related
- Sector hub: All tracked pharma companies